Epizyme, Inc., a clinical-stage biopharma company developing epigenetic therapies, has earned a $10 million milestone payment from GlaxoSmithKline (GSK). The payment follows GSK’s initiation of GLP toxicology studies for a first-in-class methyltransferase inhibitor discovered by Epizyme and licensed to GSK.

“We are pleased to achieve another milestone under our collaboration with GSK, further validating the strength of our epigenetic approach and drug discovery platform, as well our success in collaborating with industry leaders like GSK,” said Susan Graf, chief business officer of Epizyme. “We are encouraged that this investigational medicine continues to advance toward the clinic.”